Atai Life Sciences plans to merge with psychedelic startup Beckley Psytech
The new company will be known as Atai Beckley…
…with Beckley Psytech shareholders receiving 31% of shares in the entity… Beckley’s lead program is a synthetic, intranasal form of 5-meo-dmt…
Original Artic (Stat News):
Atai Life Sciences plans to merge with psychedelic startup Beckley Psytech
Artwork Fair Use: Jynto
Recent Comments